Clinical Trial Update: Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating neoadjuvant toripalimab in gastric/gastroesophageal junction adenocarcinoma with dMMR/MSI-H status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN